Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study

AIMS: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso‐enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug–drug interaction may occur. I...

詳細記述

保存先:
書誌詳細
出版年:Br J Clin Pharmacol
主要な著者: Belderbos, Bodine P.S., Hussaarts, Koen G.A.M., van Harten, Leonie J., Oomen‐de Hoop, Esther, de Bruijn, Peter, Hamberg, Paul, van Alphen, Robbert J., Haberkorn, Brigitte C.M., Lolkema, Martijn P., de Wit, Ronald, van Soest, Robert J., Mathijssen, Ron H.J.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2019
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475678/
https://ncbi.nlm.nih.gov/pubmed/30737835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13889
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料